Trump’s Most-Favored-Nation Drug Plan: A Price Revolution or Political Gamble?

In a move that could reshape the U.S. healthcare and pharmaceutical landscape, President Donald J. Trump has announced historic agreements with major drug manufacturers Eli Lilly and Novo Nordisk—a bold step under his “Most-Favored-Nation (MFN) Pricing” initiative.